Department of Surgery
Biotechnology | Cancer Biology | Fluids and Secretions | Neoplasms | Therapeutics
Triple-negative breast cancer is a phenotype of breast cancer where the expression level of estrogen, progesterone and human epidermal growth factor receptor 2 (HER2) receptors are low or absent. It is more frequently diagnosed in younger and premenopausal women, among which African and Hispanic have a higher rate. Cold atmospheric plasma has revealed its promising ant-cancer capacity over the past two decades. In this study, we report the first cold plasma jet delivered by the Canady Cold Plasma Conversion Unit and characterization of its electric and thermal parameters. The unit effectively reduced the viability of triple-negative breast cancer up to 80% without thermal damage, providing a starting point for future clinical trials.
triple-negative breast cancer, cold atmospheric plasma, cold plasma device
Rights and Permissions
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
DOI of Published Version
Cheng, X.; Rowe, W.; Ly, L.; Shashurin, A.; Zhuang, T.; Wigh, S.; Basadonna, G.; Trink, B.; Keidar, M.; Canady, J. Treatment of Triple-Negative Breast Cancer Cells with the Canady Cold Plasma Conversion System: Preliminary Results. Plasma 2018, 1, 218-228. https://doi.org/10.3390/plasma1010019
Cheng X, Rowe W, Ly L, Shashurin A, Zhuang T, Wigh S, Basadonna G, Trink B, Keidar M, Canady J. (2018). Treatment of Triple-Negative Breast Cancer Cells with the Canady Cold Plasma Conversion System: Preliminary Results. Open Access Articles. https://doi.org/10.3390/plasma1010019. Retrieved from https://escholarship.umassmed.edu/oapubs/3592
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.